Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 14/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598321 | 0.68 | NOTUM (0.42) | NOTUMNR1H2NR1H3CA12CA9 | |
| SCHEMBL17995256 | 0.67 | MCL1 (0.61) | MEN1KMT2A | |
| SCHEMBL6049263 | 0.66 | MCL1 (0.44) | NR1H2MEN1KMT2ANR1H3CA12 | |
| SCHEMBL4656095 | 0.66 | NR1H2 (0.42) | SIGMAR1NR1H2MEN1KMT2ANR1H3 | |
| SCHEMBL387114 | 0.65 | MCL1 (0.43) | NR1H2MEN1KMT2ANR1H3CA12 | |
| SCHEMBL29524946 | 0.65 | NR1H2 (0.55) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL3542987 | 0.65 | NOTUM (0.40) | NOTUMSIGMAR1NR1H2MEN1KMT2A | |
| SCHEMBL6715677 | 0.65 | HTR2A (0.53) | SIGMAR1NR1H2 | |
| SCHEMBL8653934 | 0.64 | KMT2A (0.46) | SIGMAR1KMT2A | |
| SCHEMBL21028079 | 0.64 | NR1H2 (0.37) | NOTUMSIGMAR1NR1H2NR1H3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | NOTUM 3876/4885SIGMAR1 2270/4885NR1H2 4/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | NOTUM 3644/4885SIGMAR1 3069/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.